Skip to main content
Top
Published in: BMC Palliative Care 1/2019

Open Access 01-12-2019 | Tympanotomy | Research article

Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites

Authors: Christina Fotopoulou, Thomas Berg, Annekristin Hausen, René Hennig, Rajiv Jalan, Massimo Malagó, Jeroen Capel, Andrea De Gottardi, Guido Stirnimann

Published in: BMC Palliative Care | Issue 1/2019

Login to get access

Abstract

Background

Malignant Ascites (MA) is a therapeutic dilemma significantly impairing patients’ quality of life (QoL). The Sequana Medical alfapump System (AP), a subcutaneous, externally rechargeable, implantable device, continually draining ascites via the urinary bladder, has been well established in liver cirrhosis, but not yet in MA. The AP-system was evaluated in cancer patients in reducing the need for large volume paracentesis (LVP).

Methods

A retrospective multicentre evaluation of all eligible patients who received an AP for MA-palliation was performed. AP was evaluated for its ability to reduce LVP and cross-correlated with adverse events (AE), survival and retrospective physician-reported QoL.

Results

Seventeen patients with median age of 63 years (range: 18–81), 70.6% female, across 7 primary tumour types were analysed. Median duration of AP-implantation was 60 min (range: 30–270) and median post-implantation hospital stay: 4 days (range: 2–24). Twelve protocol-defined AE occurred in 5 patients (29.4%): 4 kidney failures, 4 pump/catheter-related blockages, 3 infections/peritonitis and 1 wound dehiscence. Median ascitic volume (AV) pumped daily was 303.6 ml/day (range:5.6–989.3) and median total AV drained was 28 L (range: 1–638.6). Median patient post-AP-survival was 111 days (range:10–715) and median pump survival was 89 days (range: 0–715). Median number of paracenteses was 4 (range: 1–15) per patient pre-implant versus 1 (range: 0–1) post-implant (p = 0.005). 71% of patients were reported to have an improvement of at least one physician reported QoL-parameters.

Conclusions

AP appears to be effective in palliating patients with MA by an acceptable morbidity profile. Its broader implementation in oncology services should be further explored.

Trial registration

NCT03200106; June 27, 2017.
Appendix
Available only for authorised users
Literature
1.
go back to reference Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.CrossRef Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42(5):589–97.CrossRef
2.
go back to reference Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7.CrossRef Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7.CrossRef
3.
go back to reference Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9.CrossRef Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1–9.CrossRef
4.
go back to reference Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care. 2012;29(7):515–21.CrossRef Malayev Y, Levene R, Gonzalez F. Palliative chemotherapy for malignant ascites secondary to ovarian cancer. Am J Hosp Palliat Care. 2012;29(7):515–21.CrossRef
5.
go back to reference Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin N Am. 2006;35(1):189–99 xi.CrossRef Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin N Am. 2006;35(1):189–99 xi.CrossRef
6.
go back to reference Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 2012;107(6):925–30.CrossRef Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 2012;107(6):925–30.CrossRef
7.
go back to reference White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE medical technology guidance. Appl Health Econ Health Policy. 2012;10(5):299–308.CrossRef White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE medical technology guidance. Appl Health Econ Health Policy. 2012;10(5):299–308.CrossRef
8.
go back to reference Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med. 2014;17(8):906–12.CrossRef Narayanan G, Pezeshkmehr A, Venkat S, Guerrero G, Barbery K. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med. 2014;17(8):906–12.CrossRef
9.
go back to reference Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31(8):76.CrossRef Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31(8):76.CrossRef
10.
go back to reference Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol. 2013;58(5):922–7.CrossRef Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol. 2013;58(5):922–7.CrossRef
11.
go back to reference Storni F, Stirnimann G, Banz V, De Gottardi A. Treatment of malignant ascites using an automated pump device. Am J Gastroenterol. 2018;113(7):1060–1.CrossRef Storni F, Stirnimann G, Banz V, De Gottardi A. Treatment of malignant ascites using an automated pump device. Am J Gastroenterol. 2018;113(7):1060–1.CrossRef
12.
go back to reference Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46(10):981–91.CrossRef Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46(10):981–91.CrossRef
13.
go back to reference Fotopoulou C, Spiers L, Pickford E, Dina R, Blagden S, Habib N. Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient. Int J Gynecol Cancer. 2013;31(15):5562–5562. https://doi.org/10.1200/jco.2013.31.15_suppl.5562 Fotopoulou C, Spiers L, Pickford E, Dina R, Blagden S, Habib N. Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient. Int J Gynecol Cancer. 2013;31(15):5562–5562. https://​doi.​org/​10.​1200/​jco.​2013.​31.​15_​suppl.​5562
Metadata
Title
Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites
Authors
Christina Fotopoulou
Thomas Berg
Annekristin Hausen
René Hennig
Rajiv Jalan
Massimo Malagó
Jeroen Capel
Andrea De Gottardi
Guido Stirnimann
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Palliative Care / Issue 1/2019
Electronic ISSN: 1472-684X
DOI
https://doi.org/10.1186/s12904-019-0497-3

Other articles of this Issue 1/2019

BMC Palliative Care 1/2019 Go to the issue